Design of SERENA-6, a phase III switching trial of camizestrant in ESR1 -mutant breast cancer during first-line treatment
Top Cited Papers
Open Access
- 1 March 2023
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 19 (8) , 559-573
Abstract
ESR1 mutation (ESR1m) is a frequent cause of acquired resistance to aromatase inhibitor (AI) plus cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), which is a first-line therapy for hormone-rec... Plain language summary Why will we perform this study? Patients with advanced breast cancer in which the cancer cells have the receptor for the hormone estrogen and/or progesterone are typically tr... Tweetable abstract SERENA-6 (NCT04964934) is an ongoing randomized, double-blind, phase III trial of camizestrant + CDK4/6i in ESR1-mutant HR+/HER2-negative advanced breast cancer during first-line...Keywords
Funding Information
- AstraZeneca
This publication has 49 references indexed in Scilit:
- Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating MutationsCancer Cell, 2018
- Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancerAnnals of Oncology, 2017
- Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast CancerFrontiers in Oncology, 2017
- Activating ESR1 Mutations Differentially Affect the Efficacy of ER AntagonistsCancer Discovery, 2017
- Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast CancerJAMA Oncology, 2016
- Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancerScience Translational Medicine, 2015
- Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degraderEndocrine-Related Cancer, 2015
- Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibilityScience, 2014
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancerNature Genetics, 2013
- SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trialsBMJ, 2013